[go: up one dir, main page]

WO2003038032A3 - Mittel zur hemmung der synthese von virusproteinen - Google Patents

Mittel zur hemmung der synthese von virusproteinen Download PDF

Info

Publication number
WO2003038032A3
WO2003038032A3 PCT/DE2002/004052 DE0204052W WO03038032A3 WO 2003038032 A3 WO2003038032 A3 WO 2003038032A3 DE 0204052 W DE0204052 W DE 0204052W WO 03038032 A3 WO03038032 A3 WO 03038032A3
Authority
WO
WIPO (PCT)
Prior art keywords
vpr
hiv
immune deficiency
inhibitors
inhibition
Prior art date
Application number
PCT/DE2002/004052
Other languages
English (en)
French (fr)
Other versions
WO2003038032A2 (de
WO2003038032A8 (de
Inventor
Hans Will
Uwe Tessmer
Karsten Bruns
Original Assignee
Hans Will
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Will filed Critical Hans Will
Priority to DE20220744U priority Critical patent/DE20220744U1/de
Priority to AU2002347102A priority patent/AU2002347102A1/en
Priority to EP02782752A priority patent/EP1439853A2/de
Publication of WO2003038032A2 publication Critical patent/WO2003038032A2/de
Publication of WO2003038032A8 publication Critical patent/WO2003038032A8/de
Publication of WO2003038032A3 publication Critical patent/WO2003038032A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft Mittel zur Hemmung von Primaten Lentiviren und insbesondere die Verwendung von PPIase-Inhibitoren als Mittel zur Hemmung von Humanen Immundefizienzviren Typ 1 und 2 (HIV-1 und HIV-2) sowie von Simian Immundefizienzviren (SIV). Anhand des Virusproteins R (Vpr) wird gezeigt, dass Inhibitoren von zellulären cis/trans Peptidylprolyl-Isomerasen (PPIasen) sowohl die Expression, Faltung, Proteinstabilität als auch die biologische Wirksamkeit von Vpr hemmen. Die anti-virale Wirkung von PPIase-Inhibitoren, speziell von CyclosporinA, beruht auf einer spezifischen Wechselwirkung von PPIasen, speziell von CyclophilinA, mit Prolinen im N-Terminus von Vpr. Anwendungsgebiete sind die antiretrovirale Therapie und Vorbeugung bei Infektionen mit Immundefizienz verursachenden Lentiviren bei Tieren und Menschen, insbesondere von AIDS oder HIV-induzierten pathologischen Erscheinungen, auch in Kombination mit anderen anti-retroviralen Medikamenten.
PCT/DE2002/004052 2001-10-25 2002-10-25 Mittel zur hemmung der synthese von virusproteinen WO2003038032A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE20220744U DE20220744U1 (de) 2001-10-25 2002-10-25 Mittel zur Hemmung von Lentiviren
AU2002347102A AU2002347102A1 (en) 2001-10-25 2002-10-25 Means for inhibition of the synthesis of viral proteins
EP02782752A EP1439853A2 (de) 2001-10-25 2002-10-25 Mittel zur hemmung der synthese von virusproteinen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153902 2001-10-25
DE10153902.9 2001-10-25

Publications (3)

Publication Number Publication Date
WO2003038032A2 WO2003038032A2 (de) 2003-05-08
WO2003038032A8 WO2003038032A8 (de) 2003-08-14
WO2003038032A3 true WO2003038032A3 (de) 2003-10-30

Family

ID=7704423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004052 WO2003038032A2 (de) 2001-10-25 2002-10-25 Mittel zur hemmung der synthese von virusproteinen

Country Status (4)

Country Link
EP (1) EP1439853A2 (de)
AU (1) AU2002347102A1 (de)
DE (1) DE20220744U1 (de)
WO (1) WO2003038032A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (de) * 1990-11-02 1992-05-06 Sandoz Ltd. Zyklosporine
WO1997033604A1 (en) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
WO2003038056A2 (en) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methods for inhibiting lentivirus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281A2 (de) * 1990-11-02 1992-05-06 Sandoz Ltd. Zyklosporine
WO1997033604A1 (en) * 1996-03-12 1997-09-18 Picower Institute For Medical Research Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
WO2003038056A2 (en) * 2001-11-02 2003-05-08 The Regents Of The University Of California Methods for inhibiting lentivirus replication

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRIGGS C J ET AL: "Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV -1.", ARCHIVES OF VIROLOGY, (1999) 144 (11) 2151-60., XP000993073 *
HUSS, RALF: "Inhibition of cyclophilin function in HIV -I infection by cyclosporin A", IMMUNOLOGY TODAY (1996), 17(6), 259-260, XP004034608 *
MINDER D ET AL: "Immunophilins and HIV -1 infection.", ARCHIVES OF VIROLOGY, (2002 AUG) 147 (8) 1531-42., XP002251068 *
MLYNAR E ET AL: "The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells.", THE JOURNAL OF GENERAL VIROLOGY. ENGLAND APR 1997, vol. 78 ( Pt 4), April 1997 (1997-04-01), pages 825 - 835, XP002251070, ISSN: 0022-1317 *
STEINKASSERER A ET AL: "Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 ( HIV -1): interference with early and late events in HIV -1 replication.", JOURNAL OF VIROLOGY, (1995 FEB) 69 (2) 814-24., XP002251069 *
STREBLOW D N ET AL: "Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A.", VIROLOGY, (1998 JUN 5) 245 (2) 197-202., XP002251067 *

Also Published As

Publication number Publication date
AU2002347102A1 (en) 2003-05-12
WO2003038032A2 (de) 2003-05-08
WO2003038032A8 (de) 2003-08-14
EP1439853A2 (de) 2004-07-28
DE20220744U1 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
CA2217737A1 (en) Thf-containing sulfonamide inhibitors of aspartyl protease
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
MY137777A (en) Inhibitors of aspartyl protease
MY115797A (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
EP1637518A3 (de) Aspartylprotease-Hemmer
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2003038032A8 (de) Mittel zur hemmung der synthese von virusproteinen
DE60130641D1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
CA2195125A1 (en) Difluorostatone antiviral agents
WO2022125378A8 (en) Combination therapy
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
AP2003002852A0 (en) Natural antibodies active against HIV virus
GB2382529A (en) Immunomodulator for the management of human immunodficiency virus (hiv) disease/infection
WO2005068492A3 (en) Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection
ZA95756B (en) Macrocyclic difluorostatone derivatives useful as antiviral agents
WO2005028442A3 (en) 2-pyridinone derivatives, having hiv inhibiting properties
EP1862471A3 (de) Pharmakologisch aktive antivirale Peptide und Verfahren zu ihrer Verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72) DELETE ""SCHUBERT, ULRICH; JENAISCHE STRASSE 51, 07407 UHLSTAEDT (DE).""

WWE Wipo information: entry into national phase

Ref document number: 2002782752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002782752

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP